{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"DLT was defined as any events that is determined to be possibly, probably, or definitely related to the combination of bortezomib and GX15-070 (as determined by the investigator) and occurring during the first cycle of treatment, irrespective of whether the toxicity resolved. Hematologic DLT measures were assessed using the continuous variables as the outcome measures (primarily nadir and percent change from baseline values) as well as categorization via Common Terminology Criteria for Adverse Events (CTCAE) version 3 standard toxicity grading.","groups":[{"description":"Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 21 days of every first course","title":"Number of Dose-limiting Toxicity (DLT) Incidents (Phase I)","type":"PRIMARY","unitOfMeasure":"Toxicity Incidents"}